BJCT-BIOJECT-needle less injection product Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BJCT-BIOJECT-needle less injection product

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: geewiz who wrote (405)	11/6/1999 2:48:00 PM
From: geewiz	Read Replies (1) of 534

From Business Week, July 19,1999 INTERNATIONAL -- EUROPEAN BUSINESS Here Come Europe's Biotech Brides (int'l edition) Their R&D is luring more big drugmakers into alliances CLUSTERS. The European biotechs excel at certain specialties, according to Ernst & Young. Companies such as Britain's Cantab Pharmaceuticals PLC and France's Transgene are developing gene-therapy technology to produce better therapeutic vaccines. Transgene, for instance, has a 10-year, $77 million contract to provide technology to Schering-Plough Corp. for gene-based vaccines to fight cancer. Other companies, such as Britain's PowderJect Pharmaceuticals PLC, which licensed its needle-less injection system to Britain's Glaxo Wellcome PLC for $283 million last year, are focusing on the technology used to deliver these DNA vaccines. Copywrite Business Week I didn't remember that 283 million dollar figure Galxo paid to Powderject!! That's only about thirty times our present market cap!! And it requires every drug to be reformulated! hold on!! art

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next